Pavmed Inc (PAVM) 13F Filing Data & Analysis (Q2 2026)

PAVM ranks #8397 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

20 institutions disclose a position in PAVM, but none treat it as a major bet — even Two Seas Capital LP, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Two Seas Capital LP has trimmed its PAVM position for two straight quarters, cutting it by $3.0M while still holding $1.7M.

PAVM is up 3.7% today, and institutions have been net buyers of $2.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PAVM reported a net loss of $12.1M over the trailing twelve months.

• Not yet profitable — net loss of $12.1M over the trailing twelve months
• Revenue declined 89.0% year over year
• Net income declined year over year, from $72.9M to -$12.1M
• Operating cash flow was negative, using $5.2M in cash
• Current ratio of 0.17x — below the conventional 1.5x liquidity buffer
• Liabilities run 0.49x equity — within a conventional range